Bright Minds Bios…
USUSDBright Minds Biosciences Inc (US:DRUG) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- brightmindsbio.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Headquarters
- CHICAGO, United States
- Management
- Ian McDonald
- Employees
- 26
- Shares outstanding
- 9.86 M
- Free float
- 6.69 M
- Market cap
- 500.21 M USD
- Insiders
- 11.94%
- Institutions
- 94.95%
- Industry (SIC)
- Pharmaceutical Preparations
- P/EP/E (Price / Earnings) — how many years of the company's profit you pay for a share. Calculated: current price ÷ net earnings per share over the last 12 months. Lower means cheaper relative to profit. Not calculated when the company has a loss (—).
- loss
- EPSEPS (Earnings Per Share) — the company's net profit over the last 12 months divided by the number of its shares, in the currency of this listing. A negative value (red) means a loss. P/E is the share price divided by EPS.
- −2.05 USD
- P/BP/B (price to book) is the market capitalisation divided by shareholders' equity from the latest balance sheet (assets minus liabilities, without minority interests). Below 1 the company is valued at less than its book equity. Banks and insurers usually trade near 1, asset-light companies much higher. Companies with negative equity have no P/B.
- 0.94
- ROEROE (return on equity) is net income over the last 12 months divided by average shareholders' equity over those 12 months. It shows how much profit the company earns on every 100 dollars of capital. Consistently above 15% is a sign of a strong business, but a high ROE can also come from heavy debt or small equity after buybacks. One-off gains (sale of a business, revaluation, tax benefit) are excluded; «!» explains why the value differs from the reported one or is unreliable. Companies with negative equity have no ROE.
- −14.6%Equity changed more than twofold over the year (share issue, spin-off, large payouts). ROE of −14.6% is unreliable, so it is not used in filters.
- FCFFCF (Free Cash Flow) — money left to the company after operating costs and investment in equipment; dividends are safest when paid from it. Calculated: operating cash flow − capital expenditure, over the last 12 months, in the reporting currency.
- −24.7 M CAD
- DebtDebt — all loans and bonds of the company per the latest report (short- and long-term), in the reporting currency. Below — how many years the company would need to repay net debt (debt minus cash) from its free cash flow: net debt ÷ FCF. Up to 3 years — good, 3–6 — moderate, over 6 — high. «Net cash» — net debt is negative.
Debt 65.6 K CAD FCF −24.7 M CAD The years shown on the page use net debt: cash on hand can be used to repay debt at any time. - 65.6 K CADnegative FCF — not covered
- Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
- NAVNAV — net asset value by the balance sheet: the company's assets minus its liabilities, the share of the company's shareholders (without other owners' stakes in its subsidiaries). Shown per share, with P/NAV — how many times the share price exceeds NAV per share (below 1 — the share costs less than its net assets on the balance sheet). Click to see what NAV is made of and its history.
Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Candles
Each candle is one trading day. The thick part runs from the open price to the close price: green — the day closed higher than it opened, red — lower. The thin line runs from the lowest to the highest price of the day. Hover or tap a day to see all four prices.
P/E
The share price divided by the company earnings per share for the last 12 months (EPS). It shows how many years the company would need to earn its current profit to «pay back» the price: a lower P/E means the stock is cheaper relative to earnings. The line has its own scale on the left.
For some companies earnings come from their quarterly reports: on the day of a new report P/E jumps (a purple tick at the bottom of the chart), between reports it changes only with the price. For others P/E uses current earnings, so before the latest report it is approximate. If earnings are negative, P/E is not shown.
My position
Visible only to you and only if this stock is among your open portfolio positions (purchases in the same currency as the chart exchange). From each purchase date there is a dashed line at the purchase price, and between it and each day close price — an area: green if the position is in profit, red if at a loss. If you sold part, the remainder is shown: a sale writes off the earliest purchases first. The day tooltip shows how many shares were in the position and the gain or loss in money and %.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Jupiter Topco LLC | 13.86% | 1.35 M | 2026-06-30 |
| McDonald (Ian) (Director… | ≈10.34% | 1.01 M | 2026-06-12 |
| Cormorant Asset Manageme… | ≈9.76% | 950 000 | 2026-04-28 |
| Cormorant Asset Manageme… | 9.25% | 900 000 | 2026-06-30 |
| Blackrock Inc. | 7.05% | 686 184 | 2026-06-30 |
| Vivo Capital, LLC | 5.73% | 557 172 | 2026-06-30 |
| Vestal Point Capital, LP | 5.6% | 545 000 | 2026-06-30 |
| Braidwell LP | 4.97% | 483 822 | 2026-06-30 |
| Driehaus Capital Managem… | 4.45% | 433 377 | 2026-06-30 |
| Balyasny Asset Managemen… | 3.55% | 345 053 | 2026-06-30 |
| Adage Capital Partners G… | 3.44% | 335 000 | 2026-06-30 |
| Point72 Asset Management… | 3.36% | 327 416 | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.97% | 191 512 | 2026-08-31 |
| MUTUAL FUND SERIES TRUST… | 1.34% | 130 013 | 2026-06-30 |
| BlackRock Funds-BlackRoc… | 0.98% | 95 655 | 2026-05-31 |
| Fidelity Salem Street Tr… | 0.83% | 81 231 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.72% | 70 125 | 2026-08-31 |
| Fidelity Covington Trust… | 0.55% | 53 328 | 2026-09-30 |
| Driehaus Mutual Funds-Dr… | 0.43% | 41 568 | 2026-06-30 |
| AdvisorShares Trust-Advi… | 0.41% | 39 822 | 2026-09-30 |
| VANGUARD SCOTTSDALE FUND… | 0.37% | 35 879 | 2026-05-31 |
| BlackRock Health Science… | 0.33% | 31 933 | 2026-06-30 |
| Fryzuk (Jeremy) (Directo… | ≈0.31% | 30 609 | 2026-02-24 |
| Vasilkevich (Alex) (Seni… | ≈0.22% | 21 750 | 2026-05-28 |
| Bottler (Nils Christian)… | ≈0.05% | 5 000 | 2026-06-03 |
| Cheung (Ryan) (Senior Of… | ≈0% | 400 | 2026-10-06 |
